Published on 22/12/2025
Understanding Global Regulatory Timelines for Drug Approvals
Introduction: The Importance of Regulatory Timing in Drug Development
Time is one of the most valuable resources in drug development. From submission to approval, regulatory review timelines significantly impact commercial launch strategies, market exclusivity, patient access, and global supply chain planning. However, these timelines vary considerably across regions, influenced by agency capacity, regulatory pathways, national guidelines, and priority programs.
This article provides a comparative overview of the review timelines for New Drug Applications (NDAs), Biologics License Applications (BLAs), and Marketing Authorization Applications (MAAs) across key regulatory agencies, including the U.S. FDA, European Medicines Agency (EMA), Japan’s PMDA, Health Canada, TGA (Australia), and others.
FDA (United States): PDUFA Timelines and Review Pathways
The U.S. Food and Drug Administration (FDA) operates under the Prescription Drug User Fee Act (PDUFA), which sets specific goals for review timeframes:
- Standard Review: 10 months from the 60-day filing date (≈12 months from submission)
- Priority Review: 6 months from filing (≈8 months
For biologics, the timelines are similar under the BLA pathway. The FDA may extend reviews by 3 months if major amendments are submitted. First-cycle approvals are common but not guaranteed. Fast Track, Breakthrough Therapy, and Accelerated Approval designations may influence review efficiency but do not alter formal PDUFA clocks.
FDA Clock Overview:
- Filing Review: 2 months
- Review Clock Starts: After Day 60
- Total Target: 8–12 months (depending on designation)
EMA (Europe): Centralized Procedure Timelines
The European Medicines Agency (EMA) reviews MAAs under the Centralized Procedure, leading to a single EU-wide approval. Key timeline components include:
- Day 0–120: Assessment Report 1 (AR1)
- Clock Stop: Sponsor responds to questions (up to 3–6 months)
- Day 121–210: Final assessment phase
- Day 210: CHMP opinion
- +67 days: European Commission decision
Total timeline is ~12–15 months including clock stop. Accelerated Assessment is available for high-priority drugs, reducing total review time to ~150 days excluding clock stop.
Comparative Timelines – PMDA, Health Canada, and Emerging Markets
PMDA (Japan): Review Timeline Under Sakigake and Standard Pathways
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) typically requires pre-submission consultations and detailed Japanese-specific data. Standard review timelines are:
- Standard Review: ~12 months post-submission
- Sakigake Fast Track: ~6 months (granted to breakthrough-designated products)
- Prioritized Review: ~9 months (for serious diseases)
Bridging studies or local Phase 1 data may add time. First-cycle approvals are common when prior PMDA advice is followed closely.
Health Canada: NDS Review Timelines
Health Canada offers a New Drug Submission (NDS) process for small molecules and biologics. Review timelines are:
- Standard Review: 300 days
- Priority Review: 180 days
- NOC/c (Conditional Approval): Available for serious conditions with promising early data
Health Canada has a strong record of first-cycle approvals. Submissions must follow Canadian Module 1 format, which varies slightly from FDA’s structure.
Australia (TGA): Prescription Medicine Registration
The Therapeutic Goods Administration (TGA) uses the following timelines:
- Standard Pathway: 255 working days
- Priority Review: 150 working days
- Provisional Approval: 6–12 months, based on Phase 2/early Phase 3 data
The TGA also participates in international collaborations such as the Access Consortium (with Canada, Singapore, and Switzerland) to harmonize reviews.
Brazil (ANVISA): Review Process and Queue Management
Brazil’s National Health Surveillance Agency (ANVISA) has improved its timelines significantly in recent years. Current expectations:
- Standard Review: ~12–15 months
- Priority Review: ~6–8 months
ANVISA has implemented a queue management system with timelines based on submission date and public health priority. Partnerships with other agencies (e.g., FDA) can support reliance pathways.
China (NMPA): Reforming Review Timelines
China’s National Medical Products Administration (NMPA) has undergone major reforms to align with ICH. New timelines include:
- Priority Review: 130 working days
- Standard Review: 200–300 working days
- Conditional Approval: Available for urgent unmet needs
Local trial data is often required, though multiregional clinical trials (MRCTs) are increasingly accepted.
Comparative Timeline Table
| Agency | Standard Review | Priority/Fast Review |
|---|---|---|
| FDA (US) | 12 months | 8 months |
| EMA (EU) | 12–15 months | 7–9 months |
| PMDA (Japan) | 12 months | 6–9 months |
| Health Canada | 10 months | 6 months |
| TGA (Australia) | 12 months | 7 months |
| ANVISA (Brazil) | 15 months | 8 months |
| NMPA (China) | 10–14 months | 6 months |
Global Submission Planning: Tips for Sponsors
- Use parallel submission strategies across ICH regions to compress launch timelines
- Engage in pre-submission meetings with each agency
- Consider priority pathways early during development
- Use reliance frameworks (e.g., ASEAN, Access Consortium) when eligible
- Ensure local regulatory format alignment, especially for Module 1
Conclusion: Time is a Competitive Advantage
Understanding and planning for regulatory review timelines is critical to global drug development success. While each region has unique procedures, harmonization efforts and accelerated pathways have significantly improved predictability and speed. Sponsors who take a proactive, data-driven approach to submission planning can better align launch dates, optimize resources, and deliver therapies to patients faster across the globe.